The African Organization for Research and Training in Cancer conference (AORTIC), happening November 5–8, 2019 brings together leading cancer specialists from around the world.
During the conference, attendees are invited to join The Max Foundation and the International and Chronic Myeloid Leukemia Foundation (iCMLf) for an interactive session for African Physicians Treating CML.
When:
Wednesday, November 6 from 5–8 PM at the Radisson Blu Hotel, adjacent to the AORTIC conference center in Maputo, Mozambique.
Discussion Topics:
In this session leading physicians and experts will discuss the following:
Get to know the speakers:
This is an opportunity to join in-person to learn from the experts and exchange valuable ideas and transformative practices. Light dinner refreshments will be served.
To reserve your place please email Arlene Harris-Buchan.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
Earlier this month, The Max Foundation celebrated the delivery of 110 BCR-ABL molecular tests to Mercy Medical Center Cambodia. The delivery was the first of its kind for Max, made possible through our 2018 Diagnostics Solidarity Fund. Two more deliveries – one to Kyrgyzstan and one to Bolivia – are in process now, and we’re hopeful there will be many more to come.
SEATTLE, Washington – May 17, 2023 – The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene, a global biotechnology company, and the BeiGene Foundation, a nonprofit charitable foundation, today announced a collaboration to provide access to BRUKINSA (zanubrutinib) for the….
The Max Foundation is pleased to announce a significant expansion of its collaboration with Pfizer to provide access to some of Pfizer’s innovative oncology portfolio to patients in low- and middle-income countries, which otherwise would have limited local access. The latest agreement increases the total number of patients benefitting from the program from 270 to 500 patients and adds Inlyta® (axitinib) an oral medicine used to treat advanced kidney cancer.
